Cells=Drugs takes a Scientific Hit

By /

cells=drugs problem

Transplanting organs is difficult because the host’s body rejects the foreign tissue. Since mesenchymal stem cells are anti-inflammatory and can modulate an immune response, one company has been trying to help the dreaded disease of severe organ rejection (GVHD or Graft vs. Host Disease). This company placed someone else’s mass manufactured stem cells in a vial in a cells=drugs product called Prochymal, the goal being to use the cells to block this formidable host immune response. The problem was that the stem cells in a vial didn’t work so well. This ultimately lead to one big pharma player pulling out of the deal to commercialize the cells as drugs. On the heels of that news comes a study this week out of Northwestern that shows that kidney transplant patients given the bone marrow of the donor did remarkably well, with 5/8 patients not needing anti-rejection drugs. The researchers filtered out the cells from the donor’s bone marrow that they wanted and tamped down the immune system of the host to make room for new the new cells to establish a secondary immune system. This concept called Chimerism means that the host has two immune systems, so it recognizes the donor kidney as it’s own tissue. The other three patients are only on a single anti-rejection drug.

So we have two approaches here that illustrate our cells=drugs problem nicely. One approach focused heavily on the commercialization of a drug-Prochymal. The drug route took the cells of young donors and mass manufactured those as a drug. The other approach takes an individualized and less pharma centric approach of using cells to prevent disease. There’s another difference-Prochymal was also used in a much harder to treat medical condition-GVHD. One the other side of the coin, the Northwestern surgical procedure was focused on preventing rejection. Why the difference here? The company behind Prochymal needed a big splash for Wall Street whereas the Northwestern physicians were simply trying to fix a problem they saw before them. This same transplant program chimed in on the cells=drugs policy, stating that the current cell transplants being performed by the program were the practice of medicine and only should be controlled under regulations meant to protect patients from communicable disease. The upshot? A customized surgical procedure that aimed to fix a clinical problem has bested the efforts of a pharma cells=drugs trial. While more research needs to be done by the Northwestern team, since almost nobody gets to forego anti-rejection drugs in this kind of transplant, 5/8 tells a significant scientific story. In addition, since these drugs are incredibly expensive and have high side effects-the patients win. Finally, because these expensive drugs are paid for by society though public funding or private health insurance premiums and may not be needed, it’s not hard to see why pharma is concerned and wants to turn your cells into drugs.

Join us for a free Regenexx webinar.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get Blog Updates by Email

We do not sell, or share your information to third party vendors.

By submitting the form you agree that you’ve read and consent to our Privacy Policy. We may use email, phone, or other electronic means to communicate information about Regenexx.

We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.

Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.

Copyright © Regenexx 2021. All rights reserved.



9035 Wadsworth Pkwy #1000
Westminster, CO 80021


*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.